Our Mission



The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.


Alfred Danielian, MD, FACC- Incoming Governor of Nevada speaks out on behalf of AED’s


ACC Rockies Chapter Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings


RSS Latest in Cardiology from ACC.org

  • New ACC Guidance Addresses Obesity Treatment Strategies Across the CV Spectrum
    As obesity continues to drive cardiovascular risk, the ACC has released two new guidance documents to support clinicians: Concise Clinical Guidance (CCG) on the medical management of obesity and a Scientific Statement focused on treating obesity in adults with heart failure.
  • Management of Recurrent Coarctation in Children
    Coarctation of the aorta accounts for 5-8% of all congenital heart disease, with an incidence of approximately four cases per 10,000 live births. It can be seen in isolation or associated with other cardiac lesions.
  • Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 Monoagonists
    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, according to two studies published in The Lancet.
  • CAPLA: Long-Term QOL Improvement With CA For Persistent AFib
    Quality of life (QOL) at three years significantly improved following catheter ablation (CA) for persistent atrial fibrillation (PsAFib), according to a secondary analysis of patients in the CAPLA clinical trial published in JACC: Clinical Electrophysiology.
  • Thrombotic Events In ATTR-CM Patients Linked to Primary LA Cardiopathy
    Primary left atrial (LA) cardiopathy appears to be linked to the high risk of thrombotic events (TE) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) independent of atrial fibrillation (AFib), CHA2DS2-VASc score and LA dilatation. This link differs from patients with other left ventricular hypertrophy (LVH) phenotypes according to a new study published in JACC: Cardiovascular […]